Program
All information is shown in the language in which it was submitted to ISPOR

Program Saturday, 16 September 2017

8:00 - 18:00
REGISTRATION HELP DESK HOURS (Grand Foyer)
8:00 - 18:00
SPEAKER READY ROOM HOURS (Caracas)
8:30 - 20:00
EXHIBIT/POSTER HALL HOURS (Nações Unidas, South Level)
8:30 - 20:00
RESEARCH POSTER PRESENTATIONS - SESSION I
8:30 - 10:30
WELCOME & FIRST PLENARY SESSION
WELCOME FROM ISPOR CEO/EXECUTIVE DIRECTOR
Speaker: Nancy S. Berg
CEO & Executive Director, ISPOR, Lawrenceville, NJ, USA
WELCOME FROM ISPOR PRESIDENT
Speaker: Shelby D. Reed, PhD, RPh bio
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
CONFERENCE PROGRAM OVERVIEW FROM PROGRAM COMMITTEE CO-CHAIRS
Speaker: Marcelo Fonseca, MD, MSc, PhD
Program Committee Co-Chair & Professor, Development and Assessment of Health Technologies, Escola Paulista de Medicina Federal University of São Paulo, Sao Paulo, Brazil
Speaker: Rosa Maria Galindo-Suarez, MHE
Program Committee Co-Chair & Prioritization Deputy Director General, General Health Council, Mexican Ministry of Health, México City, Mexico
Speaker: Stephen Doral Stefani, MD
Program Committee Co-Chair & Medical Auditor, Head of Oncology Unit, UNIMED, Porto Alegre, Brazil
FIRST PLENARY SESSION: LATIN AMERICAN HEALTH SYSTEMS REFORM: OPPORTUNITIES AND CHALLENGES
Presented in Portuguese and Spanish with simultaneous English/Portuguese/Spanish interpretation

Ask a Question→

The World Health Organization (WHO) has proposed universal health care coverage (UHC) as a strategy to fight inequity in access to health care, particularly in low- to middle-income countries. Since then, a number of countries in Latin America are implementing reform of their health care systems. Successful execution of UHC in the region poses a challenge, especially in the highly decentralized Latin American health care systems where much debate still exists on health policy. This multistakeholder session will focus on the current status, related challenges, and future opportunities to build more sustainable and equitable health systems in Latin America. 
Moderator: Eduardo González-Pier, PhD
Distinguished Visiting Fellow, Center for Global Development, Washington, DC, USA
Speaker: Rubén Torres, MD, PhD
Dean, ISALUD University, Buenos Aires, Argentina
Speaker: Mauricio Vargas Fuentes, MD, MSc
Director, Public Health School, Universidad de Costa Rica and Secretariat, Latin America Alliance for Global Health, ALASAG, San Pedro, San Jose, Costa Rica
Speaker: Jesús Ancer Rodriguez, MD
Secretary, General Health Council, Mexico City, Mexico
Speaker: Jairnilson Silva Paim, MMed, PhD
Professor, Health Policy and Planning, Health Situation Analysis and Urban Violence and Health, Instituto de Saúde Coletiva, Federal University of Bahia, Bahia, Brazil
Speaker: Tomás Pippo Briant, Msc
Coordinator, Medicine, Technology, and Health Research Unit, Pan America Health Organization (PAHO) / Americas office of WHO in Brazil, Brasilia, Brazil
10:30 - 11:00
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
11:00 - 12:00
BREAKOUT SESSION

11:00 - 12:00
Room: Comandatuba 2

IP1: VALUE FRAMEWORKS: IS IT POSSIBLE TO ESTABLISH IN LATIN AMERICA? (Invited Issue Panel)

Presented in English and Spanish with simultaneous English/Portuguese/Spanish interpretation
Moderator:

Rafael Alfonso Cristancho, MD, PhD, MSc, Lead Analytics and Innovation, Value Evidence and Outcomes, GSK, Collgeville, PA, USA

Panelists:

Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

Aurelio Mejia, MSc, Senior Economist, Health Technology Assessment, Instituto de Evaluación Tecnológica en Salud, Bogotá, Colombia

Richard J. Willke, PhD, Chief Science Officer, International Society for Pharmacoeconomics and Outcomes Research, Lawrenceville, NJ, USA bio


11:00 - 12:00
Room: Comandatuba 1

IP2: DADOS DO MUNDO REAL (RWD) PARA O APOIO AO DESENVOLVIMENTO DE POLITICAS DE SAUDE E À UTILIZAÇÃO PONDERADA DE BIOLÓGICOS E BIOSSIMILARES NA AMÉRICA LATINA: O QUE APRENDEMOS COM O PASSADO E COMO ESTÁ A MOLDAR O FUTURO?

Presented in Portuguese
Moderator:

Andreia Ribeiro, PhD, Engagement Manager, Market Access and P&R Practice, Lifescience Dynamics, Boston, MA, USA

Panelists:

Ricardo Garcia, MD, MBA, Director, CLAPBio, Latin American Research Center of Biotechnology, Rio de Janeiro, Brazil

Fabricio Collares, MD, PhD, Regional Medical Director LATAM, EMD Serono, Miami, FL, USA

Lindemberg Assuncao, PharmD, MS, Chief of Therapeutic Sector at EBSERH, Complexo Hospitalar Universitário Prof. Edgard Santos, Salvador BA, Brazil


11:00 - 12:00
Room: Comandatuba 3
W1: MÉTODOS EM EVOLUÇÃO PARA A GERAÇÃO DE EVIDÊNCIAS DE MUNDO REAL EM MERCADOS MADUROS E EMERGENTES
Presented in English and Portuguese
Discussion Leaders:

Gabriela Tannus Branco Araujo, MSc., Research, AxiaBio, São Paulo, Brazil

David Thompson, PhD, Senior Vice President, Real-World Evidence & Insights, inVentiv Health, Princeton, NJ, USA

Marcelo Fonseca, MD, MSc, PhD, Professor, Federal University of São Paulo, São Paulo, Brazil


11:00 - 12:00
Room: Transamérica Auditorium
P1: CANCER STUDIES
CA1 presented in Spanish; CA2, CA3, CA4 presented in Portuguese
Moderator: Constanza Vargas, MSc
Pontificia Universidad Catolica de Chile, Santiago, Chile

CA1

11:00 - 11:15

COMPARATIVE ASSESSMENT OF LATIN AMERICAN HTA APPRAISALS FOR ONCOLOGY

Arvin-Berod C1, Benjamin N2, Martel M3
1Xcenda Switzerland GmbH, Bern, Switzerland, 2Xcenda, LLC, Palm Harbor, FL, USA, 3Xcenda (UK) Ltd, London, UK

CA2

11:15 - 11:30

THE MULTI-CRITERIA DECISION ANALYSIS IN THE PRIORITY SETTING OF EMERGING MEDICINES

Nascimento A, Almeida RT
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

CA3

11:30 - 11:45

ANALYTICAL HIERARCHICAL PROCESS FOR EVALUATION OF FIRST LINE TREATMENT OF METASTATIC HER2 OVEREXPRESSED BREAST CANCER FROM BRAZILIAN HEALTH SYSTEM PERSPECTIVE

Valle PM1, Vianna CM1, Mosegui GB2, Leal MC3, de Oliveira FS3, Lima IJ4, Silva FV1, Rodrigues MP3
1Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2Universidade Federal Fluminense, Niterói, Brazil, 3UERJ, Rio de Janeiro,, Rio de Janeiro, Brazil, 4Instituto Tecnológico de Aeronáutica, São José dos Campos, Brazil

CA4

11:45 - 12:00

COMPARISON OF THE ASSESSMENTS AND RECOMMENDATIONS ISSUED BY BRAZIL’S CONITEC AND CANADA’S CADTH FOR SELECT ONCOLOGY DRUGS

Montilva J, Perrinjaquet M, Silva M, Degun R
Navigant Consulting, London, UK

11:00 - 12:00
Room: São Paulo 3
P2: HEALTH TECHNOLOGY ASSESSMENT STUDIES
HT1, HT2, HT3 presented in Portuguese; HT4 presented in Spanish
Moderator: Homero A. Monsanto, PhD
Merck & Co., Carolina, Puerto Rico

HT1

11:00 - 11:15

CONITEC REIMBURSEMENT DECISIONS: IS THERE A COST-UTILITY DECISION THRESHOLD?

Lemmer T, Saad R, Piedade A, Julian GS, Moreira Ed, de Oliveira RW
Evidências - Kantar Health, São Paulo, Brazil

HT2

11:15 - 11:30

DISINVESTMENT OF HEALTH TECHNOLOGIES BY THE NATIONAL COMMISSION FOR TECHNOLOGY INCORPORATION FROM 2012-2016

Caetano R1, Steffen RE2, Silva RM3, Biz AN1, Oliveira IA1, Santana PK1, Pedro ÉM1
1Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2Social Medicine Institute/UERJ, Rio de Janeiro, Brazil, 3Escola Nacional de Saúde Pública Sergio Arouca FIOCRUZ, Rio de Janeiro, Brazil

HT3

11:30 - 11:45

AVANÇOS DO MONITORAMENTO DO HORIZONTE TECNOLÓGICO NO BRASIL

Souza AB1, Teixeira Vidal A1, Gomes PT2
1Department of Management and Incorporation of Health Technology, National Committee for Health Technology Incorporation (CONITEC), Brazilian Ministry of Health, Brasília, Brazil, 2Ministry of Health, Brasilia, Brazil

HT4

11:45 - 12:00

DEVELOPING AND PILOTING A VALUE FRAMEWORK AND A TOOL TO INFORM THE “EVIDENCE-TO-DECISION MAKING” PROCESS

Alcaraz A1, Hernandez-Vasquez A1, Garcia Marti S1, Bardach A2, Ciapponi A3, Pichon-Riviere A1, Augustovski F1
1Institute for Clinical Effectiveness and Health Policy (IECS), CABA, Argentina, 2National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina, 3Cochrane Center Argentina, CABA, Argentina
12:00 - 15:00
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING
12:30 - 13:30
EDUCATIONAL SYMPOSIUM
12:30 - 13:30
Room: Comandatuba 2
ADVANCES IN GENERATING REAL-WORLD EVIDENCE IN LATIN AMERICA AND ITS VALUE FOR THE HEALTH CARE SYSTEM
Presented in English with simultaneous Spanish interpretation

Symposium Description

(Sponsored by QuintilesIMS)

13:45 - 14:45
EDUCATIONAL SYMPOSIUM
13:45 - 14:45
Room: Comandatuba 2
SUSTAINABILITY OF VACCINATION PROGRAMS IN LATIN AMERICA: NEW APPROACHES AVAILABLE UNDER GOVERNMENT BUDGET RESTRICTIONS
Presented in English with simultaneous Portuguese/Spanish interpretation

Symposium Description

(Sponsored by GlaxoSmithKline)

15:00 - 16:00
BREAKOUT SESSION

15:00 - 16:00
Room: Comandatuba 1

IP3: LOS DESAFIOS DE LAS ENFERMEDADES RARAS EN LA REGIÓN: EQUILIBRIO ENTRE EL ACCESO Y ACCESIBILIDAD (Invited Issue Panel)

Presented in Spanish
Moderator:

Gabriela Tannus, MBA, MSc, Owner & Health Economics Director, Axia.Bio Life Sciences International, Miami, FL, USA

Panelists:

Diego Rosselli, MD, MEd, MHP, Profesor Adjunto, Economía de la Salud, Pontificia Universidad Javeriana, Bogotá, Colombia

Angela Chaves, DO, Presidente, Federación Colombiana de Enfermedades Raras, Bogotá, Colombia


15:00 - 16:00
Room: Comandatuba 2
W2: APPROACHES FOR PRIORITY SETTING: IS THERE A BEST WAY?
Presented in English with simultaneous English/Portuguese/Spanish interpretation
Discussion Leaders:

Praveen Thokala, MASc, PhD, Research Fellow, ScHARR, The University of Sheffield, Sheffield, UK

Manuel A. Espinoza, MD, MSc, PhD, Profesor, Departamento de Salud Pública y Jefe, Unidad de Evaluaciones de Tecnologías Sanitarias - Centro de Investigación Clínica, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, e Investigador Visitante Honorario, Centro para la Economía de Salud, Universidad de York, York, UK

Aurelio Mejia, MSc, Senior Economist, Health Technology Assessment, Instituto de Evaluación Tecnológica en Salud, Bogotá, Colombia


15:00 - 16:00
Room: Comandatuba 3
W3: EVALUACIONES DE TECNOLOGÍAS SANITARIAS (ETS) Y PRECIOS DE REFERENCIA INTERNACIONAL (PRI): ¿CÓMO SE ESTÁ PREPARANDO LA INDUSTRIA FARMACÉUTICA PARA OPTIMIZAR LA EVIDENCIA Y EL VALOR DE SU INNOVACIÓN?
Presented in Spanish
Discussion Leaders:

Mónica Martín de Bustamante, Managing Director, CBPartners, New York, NY, USA

J. Jaime Caro, MDCM, FACP, FRCPC, Adjunct Professor of Medicine & Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada

Rafael Alfonso Cristancho, MD, MSc, PhD, Director, Value Evidence Analytics, Value Evidence Outcomes, R&D, Global Medical GlaxoSmithKline, Collegeville, PA, USA

Diego F Guarin, MD, MPH, MA, Senior Director, HEOR & HTA Strategy, HEOR & HTA, Latin America, Merck-Serono, Billerica, MA, USA


15:00 - 16:00
Room: Transamérica Auditorium
P3: COST-EFFECTIVENESS STUDIES
CE1 presented in English; CE2 and CE3 presented in Spanish; CE4 presented in Portuguese
Moderator: Ruben Rojas, BSc, MSc
Pontificia Universidad Catolica de Chile, Santiago, Chile

CE1

15:00 - 15:15

COST-UTILITY ANALYSIS (CUA) OF TARGETED INTRAOPERATIVE RADIOTHERAPY ALONE (TARGIT-A) IN THE BRAZILIAN EARLY BREAST CANCER PATIENTS

Vaidya A1, Vaidya P2, Both B3
1University of Alberta, Edmonton, AB, Canada, 2O-Zone 2.0 HEOR Consultancy, Edmonton, AB, Canada, 3Carl Zeiss Meditec AG, Oberkochen, Germany

CE2

15:15 - 15:30

EVALUACIÓN DE LA COSTO-EFECTIVIDAD DE LA PRUEBA DE SECUENCIACIÓN COMPLETA DEL GEN CFTR POR TÉCNICA SANGER PARA PORTADORES ASINTOMÁTICOS EN POBLACIÓN COLOMBIANA DE PRIMER, SEGUNDO Y TERCER GRADO DE CONSANGUINIDAD CON HISTORIA FAMILIAR DE FIBROSIS QUÍSTICA.

Andrade E1, Diaz JA2
1Universidad Nacional de Colombia, Bogota, Colombia, 2Universidad Nacional de Colombia, Bogotá D.C., Colombia

CE3

15:30 - 15:45

COSTO-EFECTIVIDAD DE LA DETECCION DE ADN DE VIRUS DE PAPILOMA HUMANO DE ALTO RIESGO PARA TAMIZAJE DE CANCER DE CUELLO UTERINO EN ECUADOR.

Henriquez-Trujillo AR1, Narváez-Moscoso IF1, Lucio-Romero RA2
1Universidad de Las Américas, Quito, Ecuador, 2Sur-Este Ltd., Quito, Ecuador

CE4

15:45 - 16:00

COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB ASSOCIATED TO CHLORAMBUCIL FOR THE TREATMENT OF SLOW-GO PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM

Ho R, Rufino C, Biondo J, Alves M
Roche Brazil, São Paulo, Brazil

15:00 - 16:00
Room: São Paulo 3
P4: BUDGET IMPACT AND COST OF ILLNESS STUDIES
BI1, B2, B3 presented in Spanish; BI4 presented in Portuguese
Moderator: Hernando Gaitan, MD, MSc
National University of Colombia, Bogota, Colombia

BI1

15:00 - 15:15

ANÁLISIS DE IMPACTO PRESUPUESTARIO DE 2 MÉTODOS DE SCREENING DE CÁNCER DE CUELLO UTERINO BASADOS EN TEST DE HPV EN ARGENTINA

Lifschitz E1, Tatti SA1, Fleider L1, Simonovich VA2
1Facultad de Medicina, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina, 2Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

BI2

15:15 - 15:30

THE ECONOMIC BURDEN OF VARICELLA IN PERU

Castillo ME1, Gutierrez R2, Monsanto H3, Rampakakis E4, Altland A5, Wolfson LJ5
1INSN (Instituto Nacional de Salud del Niño), Breña, Lima, Peru, 2Merck Sharp & Dohme Peru S.R.L, Lima, Peru, 3Merck Sharp & Dohme IA LLC, Carolina, PR, PR, 4JSS Medical Research, Montreal, QC, Canada, 5Merck & Co., Inc., Kenilworth, NJ, USA

BI3

15:30 - 15:45

COSTOS DE LA FIBRILACIÓN AURICULAR EN COLOMBIA

Romero Prada ME1, Lancheros J1, Alfonso Quiñones PA2, Marrugo Figueroa RD3, Peñuela IA3, Mendoza F4, Herran Diazgranado SE3
1Salutia Foundation - Research center in economy, management and health technologies., Bogota, Colombia, 2Salutia Foundation, Bogotá, Colombia, 3Bayer, Bogotá, Colombia, 4Clinica Shaio, Bogota, Colombia

BI4

15:45 - 16:00

BURDEN AND COST OF CANCER TREATMENT IN THE PRIVATE HEALTHCARE SETTING IN SÃO PAULO STATE

Julian GS1, Carneseca EC2, Sicchieri MP2
1Evidências - Kantar Health, São Paulo, Brazil, 2Proestat, Ribeirão Preto, Brazil
16:00 - 16:15
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
16:15 - 17:15
BREAKOUT SESSION

16:15 - 17:15
Room: Comandatuba 2

IP4: COST-EFFECTIVENESS THRESHOLDS IN LATIN AMERICA: WHAT CAN WE LEARN FROM REGIONAL AND INTERNATIONAL EXPERIENCES? (Invited Issue Panel)

Presented in English, Spanish, and Portuguese with simultaneous English/Portuguese/Spanish interpretation
Moderator:

Andres Pichon-Riviere, MD, MSc, PhD, Director, Health Technology Assessment and Economic Evaluation, Institute for Clinical Effectiveness and Health Policy (IECS), CABA, Argentina

Panelists:

Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

Vania Cristina Canuto Santos, MSc, Deputy Director, Department of Management and Incorporation of Health Technology – DGITS, CONITEC, Brazilian Ministry of Health, Brasília, Brazil

Hector Castro, MD MsC PhD, Director of Drugs Incorporation, Colombian Ministry of Health, Bogota, Colombia


16:15 - 17:15
Room: Comandatuba 1

IP5: DESAFIOS NOS SISTEMAS DE SAÚDE DA AMÉRICA LATINA: QUAIS EVIDÊNCIAS DE MUNDO REAL SÃO NECESSÁRIAS PARA ESTIMAR VALOR DE EQUIPAMENTOS MÉDICO-ASSISTENCIAIS E TESTES DIAGNÓSTICOS EM UM PROCESSO DE AVALIAÇÃO DE TECNOLOGIAS EM SAÚDE?

Presented in Portuguese
Moderator:

Bruno Riveros, MSc, MSc, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK

Panelists:

Eduardo Coura Assis, MsC Gestão em Saúde Pública, Consultor, Ministério da Saúde, Brasilia, Brazil

Cristina Nunes Ferreira, MBA, Sr. Manager, Reimbursement & Health Economics for LATAM, Edwards Lifesciences Latam, São Paulo, Brazil

Charles Cachoeira, MD, MBA, Global Director Market Access, Roche, Tucson, AZ, USA


16:15 - 17:15
Room: Comandatuba 3
W4: INCORPORACIÓN DE REPRESENTANTES DE PACIENTES EN PROCESOS DE DECISIÓN DE COBERTURA EN SALUD: AVANCES Y DESAFÍOS PARA LATINOAMÉRICA
Presented in Spanish
Discussion Leaders:

Manuel A. Espinoza, MD, MSc, PhD, Professor, Department of Public Health & Chief, Unit of Health Technology Assessment - Center for Clinical Research, Catholic University of Chile, Santiago, Chile and Honorary Visiting Fellow, Centre for Health Economics, University of York, York, UK

Báltica Cabieses, MSc, PhD, Profesora, Facultad de Medicina - Clínica Alemana, Universidad del Desarrollo, Santiago, Chile

Cecilia Rodriguez, MPH, Directora, Fundación Me Muevo, Santiago, Chile


16:15 - 17:15
Room: São Paulo 3
P5: INFECTIOUS DISEASE STUDIES
IN1, IN3, IN4 presented in Spanish; IN2 presented in Portuguese
Moderator: Diego Rosselli, MSc, MEd, MD
Pontificia Universidad Javeriana, Bogota, Colombia

IN1

16:15 - 16:30

WITHDRAWN

IN2

16:30 - 16:45

PREDICTING DENGUE FEVER OUTBURSTS IN BRAZIL: AN EMPIRICAL MODEL BASED ON CLIMATIC PARAMETERS

Fahham L, Ueda A, Teich V
SENSE Company, São Paulo, Brazil

IN3

16:45 - 17:00

DETERMINANTES DE LA CALIDAD DE VIDA RELACIONADA CON LA SALUD EN PACIENTES CON VIH/SIDA EN UNA ASEGURADORA EN SALUD EN COLOMBIA.

Muñoz-Galindo IM1, Diaz JA2, Arevalo HO1, Guarin NE1, Hoyos-Beltrán FJ1, Moreno JA1
1Salud Total EPS, Bogotá D.C., Colombia, 2Universidad Nacional de Colombia, Bogotá D.C., Colombia

IN4

17:00 - 17:15

COST ASSESSMENT OF ACQUIRED RESISTANT BACTERIAL INFECTION IN A HOSPITAL IN THE DOMINICAN REPUBLIC

Mouly M1, Puello Guerrero A2, Dumartin C1, Silva ML1, Aulois-Griot M1
1University of Bordeaux, Bordeaux, France, 2Universidad Autónoma de Santo Domingo, Public Health School, Santo Domingo, Dominican Republic

16:15 - 17:15
Room: Transamérica Auditorium
P6: RESEARCH ON METHODS STUDIES
Presented in Portuguese
Moderator: Gabriela Tannus, MBA, MSc
Axia.Bio Life Sciences International, Miami, FL, USA

RM1

16:15 - 16:30

DECISION MAKING CLINICAL SCENARIOS AS A TOOL IN HTA PROCESS

Santoro Neto L
Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

RM2

16:30 - 16:45

LACK OF STANDARDIZED METHODS FOR HANDLING MULTIPLES SOURCES FOR MODEL PARAMETERS: A SYSTEMATIC REVIEW

Ribeiro RA1, Bertoldi EG2, Leal LF3, Stella SF4
1IATS & HTAnalyze, Porto Alegre, Brazil, 2Universidade Federal de Pelotas, Pelotas, Brazil, 3Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 4IATS, Porto Alegre, Brazil

RM3

16:45 - 17:00

COST-EFFECTIVENESS THRESHOLDS: REVIEW OF CASES AROUND THE WORLD

Santos AS1, Guerra-Junior Aa2, Brandão CM1
1Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 2SUS Collaborating Centre - CCATES - Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

RM4

17:00 - 17:15

DETERMINING THE BRAZILIAN POPULATION HEALTH STATUS: ESTIMATE OF HEALTH PRODUCTION FUNCTION

Gobi JR, Paschoalino PA, Costa CK, Cunha MS
Universidade Estadual de Maringá, Maringá-PR, Brazil
17:30 - 18:30
BREAKOUT SESSION

17:30 - 18:30
Room: Comandatuba 2

IP6: TECHNOLOGY ENABLED PATIENT ADHERENCE PROGRAMS AS A SOURCE OF REAL-WORLD EVIDENCE: OPPORTUNITIES IN LATIN AMERICA

Presented in English with simultaneous English/Portuguese/Spanish interpretation
Moderator:

Sandeep Duttagupta, PhD, Vice President, CBPartners, New York, NY, USA

Panelists:

Diego F Guarin, MD, MPH, MA, Senior Director, HEOR & HTA Strategy, HEOR & HTA, Latin America, Merck-Serono, Billerica, MA, USA

Miguel Martin de Bustamante, BA, Senior Associate, CBPartners, San Francisco, CA, USA


17:30 - 18:30
Room: Comandatuba 1
W5: AVALIAÇÃO DE VALOR EM MEDICAL DEVICES NA PERSPECTIVA LATINO AMERICANA (Invited Workshop)
Presented in Portuguese and Spanish
Discussion Leaders:

Ramiro E. Gilardino, MD, MSc, Director, Global Networks Latin America, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), Lawrenceville, NJ, USA

Silvio Mauro Junqueira Junior, MD, Health Economics & Market Access Senior Manager, Health Economics, Johnson & Johnson Medical Brazil, São Paulo, Brazil

Lucila Rey-Ares, MD; MSc, Lead, Health Technology and Audit Committee, CEMIC, Buenos Aires, Argentina

Marcelo Katz, MD, Senior Researcher, Value Management Office, Hospital Israelita Albert Einstein, Sao Paulo, Brazil


17:30 - 18:30
Room: São Paulo 3
P7: HEALTH SERVICES RESEARCH STUDIES
HS1, HS2, HS3 presented in Spanish; HS4 presented in English
Moderator: Rafael Alfonso, MD, PhD, MSc
GSK, Collgeville, PA, USA

HS1

17:30 - 17:45

CARACTERIZACIÓN DEL RIESGO CARDIOVASCULAR POR FACTORES ASOCIADOS: ANÁLISIS DE BASE DE DATOS DE UNA ASEGURADORA COLOMBIANA

Romero Prada ME, Acero Acero G, Huerfano LM
Fundación Salutia, Bogotá, Colombia

HS2

17:45 - 18:00

RESULTADOS DE LA IMPLEMENTACIÓN DE UNA ESTRATEGIA COMBINADA DE EDUCACIÓN Y GESTIÓN DE PACIENTES EN CENTROS DE ATENCIÓN PRIMARIA DE ARGENTINA

Prestes M1, Gayarre MA2, Elgart JF1, Rucci E3, Paganini JM4, Gagliardino JJ1
1CENEXA. Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET), La Plata, Argentina, 2Secretaría de Salud, Municipalidad de La Matanza, La Matanza, Argentina, 3III-LIDI, Facultad de Informática, Universidad Nacional de La Plata, La Plata, Argentina, La Plata, Argentina, 4Centro INUS. UNLP. Facultad de Ciencias Médicas. La Plata, Argentina., La Plata, Argentina

HS3

18:00 - 18:15

ECONOMIC BURDEN OF HERPES ZOSTER (“CULEBRILLA”) IN LATIN AMERICA

Rampakakis E1, Pollock C1, Vujacich C2, Neto J3, Covarrubias A4, Monsanto H5, Johnson KD6
1JSS Medical Research, Montreal, QC, Canada, 2Fundación Centro de Estudios Infectológicos (FUNCEI), Buenos Aires, Argentina, 3Unifesp-EPM, São Paulo, Brazil, 4Hospital Civil de Guadalajara, Guadalajara, Mexico, 5Merck Sharp & Dohme IA LLC, Carolina, PR, PR, 6Merck & Co., Inc., Kenilworth, NJ, USA

HS4

18:15 - 18:30

FINANCIAMIENTO DE ENFERMEDADES HUÉRFANAS Y RARAS EN LATINOAMÉRICA

Carrera-Acosta L1, Del Carmen J1, Flores-Benites V2, Barragan M2, Flores-Benites V3, Espinoza DH3
1Universidad Nacional Mayor de San Marcos, LIMA, Peru, 2Fondo Intangible Solidario de Salud- Seguro Integral de Salud, Lima, Peru, 3Ministerio de Salud del Perú, Lima, Peru

17:30 - 18:30
Room: Transamérica Auditorium
P8: PRICING AND POLICY STUDIES
PR1 presented in Portuguese; PR2, PR3, PR4 presented in Spanish
Moderator: Diego F. Guarín, MD, MPH, MA
Merck KGaA, Billerica, MA, USA

PR1

17:30 - 17:45

A CONSULTA PÚBLICA COMO INSTRUMENTO DE DIÁLOGO E NEGOCIAÇÃO ENTRE INDÚSTRIA E GOVERNO

Silva AS1, Pires Mega T1, Rabelo RB2
1Brazilian Ministry of Health, Brasilia, Brazil, 2Department of Management and Incorporation of Health Technology, National Committee for Health Technology Incorporation (CONITEC), Brazilian Ministry of Health, Brasília, Brazil

PR2

17:45 - 18:00

THE EFFICIENCY PATH TO UNIVERSAL HEALTH COVERAGE: DERIVATION OF COST-EFFECTIVENESS THRESHOLDS BASED ON HEALTH EXPENDITURES AND LIFE EXPECTANCY. UPDATED COUNTRY-LEVEL ESTIMATES FOR 194 COUNTRIES

Pichon-Riviere A1, Augustovski F2, Garcia Marti S3
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 2Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina, 3IECS-Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

PR3

18:00 - 18:15

LIMITACIONES DE LAS EVALUACIONES ECONÓMICAS EN SALUD EN LA ASIGNACIÓN DE RECURSOS PARA MEDICAMENTOS PARA ENFERMEDADES RARAS: UN SCOPING REVIEW

Quirland-Lazo C1, Paredes Fernandez D1, Lenz Alcayaga R2
1Universidad de Chile, Santiago, Chile, 2Lenz Consultores, Santiago, Chile

PR4

18:15 - 18:30

IMPACT OF USING EXTERNAL REFERENCE PRICING (ERP) AND HEALTH TECHNOLOGY ASSESSMENT (HTA) AS PART OF COST-CONTAINMENT POLICIES: COMPARISON OF PRICES IN LATIN AMERICA

Heredia E1, Ribeiro A2
1Lifescience Dynamics, London, UK, 2Lifescience Dynamics, Boston, MA, USA

17:30 - 18:30
Room: Comandatuba 3
F1: REGULATION IN HEALTH SYSTEMS AND EQUITY: LESSONS LEARNED AND FUTURE PERSPECTIVES FROM AN INEQUITABLE REGION IN THE WORLD
Presented in Portuguese and Spanish
Moderator:

Aurelio Mejia, MSc, Senior Economist, Health Technology Assessment, Instituto de Evaluación Tecnológica en Salud, Bogotá, Colombia

Speakers:

Edward M.A. Mezones-Holguín, MD, MSc, Jefe, Escuela de Postgrado, Universidad San Ignacio de Loyola, Lima, Peru

Natalia Jorgensen, MSc, Advisor, Ministry of Health, Buenos Aires, Argentina

Baltica Cabieses, PhD, Social Epidemiologist, Programa de Estudios Sociales en Salud, Instituto de Ciencias e Innovacion en Medicina, Universidad del Desarrollo, Santiago, Chile

Raquel Medeiros Lisbôa, MD, General Manager, Healthcare Regulation, Agencia Nacional de Saude Complementar, Rio de Janeiro, Brazil

18:30 - 19:30
RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION I
18:30 - 20:00
EXHIBITORS' RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.